U.S. Preventive Medicine and deCODE Genetics Sign Letter of Intent to Expand Personalized Medicine Platform
U.S. Preventive Medicine, a leading provider of prevention and corporate wellness programs, and deCODE Genetics, announced today they have signed a letter of intent to expand their businesses in the U.S. and internationally by adding genetic testing to their array of wellness and personalized medicine services.
Dallas, TX and Reykjavik, Iceland (PRWEB) April 4, 2008 -- U.S. Preventive Medicine®, (www.USPreventiveMedicine.com) the leader in prevention, and deCODE Genetics, the global leader in gene discovery, today announced they have signed a letter of intent to add genetic testing to expand both companies’ personalized medicine services in the U.S. and internationally.
“The signing of the letter of intent with deCODE is significant because we will be the first entity in the U.S. and internationally to offer a full continuum of geographically dispersed, comprehensive solutions for personalized medicine including preventive care, wellness and disease management,” said Christopher Fey, Chairman and CEO of U.S. Preventive Medicine. “We are very excited because our consumer, employer and physician customers will now be able to take advantage of a wide range of innovative personalized medicine services, including an opt-in genetic testing program for clients of our Centers for Preventive Medicine and members of The Prevention Plan. Our goal is to make the most advanced prevention strategies -- including more precise risk stratification -- available to informed consumers who want to use the best medicine has to offer to enjoy more good years.”
Fey said U.S. Preventive Medicine’s expansion into personalized medicine is the next step in the company’s plan to provide practical solutions at every point in the healthcare continuum both nationally and internationally.
“The relationship with U.S. Preventive Medicine will offer us another platform to provide our genetic testing and personal genetics services through an innovative business model encompassing Centers for Preventive Medicine, as well as its new Prevention Plan health benefits,” says Kári Stefánsson, M.D., CEO of deCODE. “This partnership gives deCODE access to an even wider distribution channel of consumers, employers and providers to share knowledge, experiences, new technologies and services, while providing the best possible preventive health programs.”
According to U.S. Preventive Medicine National Policy Advisor and former Secretary of the U.S. Department of Health & Human Services, Gov. Tommy Thompson, “The addition of deCODE’s DNA profiling services as a option for the individuals the company assists is a natural evolution in the direction of the demand for personalized medicine. This is a very important step for U.S. Preventive Medicine in their role as the leader of this crucial area of health care.”
About U.S. Preventive Medicine: U.S. Preventive Medicine®, a privately owned company, is building the first personalized medicine business in the United States and internationally focused on prevention. They offer employers, government agencies and consumers proprietary products that include The Prevention Plan™, a groundbreaking personalized wellness program delivered online to individuals; The Prevention Plan CM™, field-based chronic disease management programs customized for employers and government agencies to reduce healthcare costs; and The Centers for Preventive Medicine®, which offer high-tech diagnostic screenings delivered to consumers in partnership with hospitals, health systems and other providers. For more information, please visit www.USPreventiveMedicine.com.
About deCODE:
deCODE is a biopharmaceutical company applying its discoveries in human genetics to the development of drugs and diagnostics for common diseases. deCODE is a global leader in gene discovery — our population approach and resources have enabled us to isolate key genes contributing to major public health challenges from cardiovascular disease to cancer, genes that are providing us with drug targets rooted in the basic biology of disease. deCODE is also leveraging its expertise in human genetics and integrated drug discovery and development capabilities to offer innovative products and services in personal genome analysis, DNA-based diagnostics, bioinformatics, genotyping, structural biology, drug discovery and clinical development. deCODE is delivering on the promise of the new genetics. Visit us on the web at www.decode.com; on our diagnostics website at www.decodediagnostics.com; and, for our pioneering personal
genome analysis service, at www.decodeme.com.
Media Contact:
Kathy Fleming, 214-548-9083
kfleming @ USPreventiveMedicine.com
This press release was distributed through eMediawire by Human Resources Marketer (HR Marketer: www.HRmarketer.com) on behalf of the company listed above.
###
Post Comment:
Trackback URL: http://www.prweb.com/pingpr.php/WmV0YS1JbnNlLUluc2UtWmV0YS1TdW1tLVplcm8=
Bookmark -
Del.icio.us |
Digg |
Furl It |
Spurl |
RawSugar |
Simpy |
Shadows |
Blink It |
My Web
|
Share The News
Submit this press release easily to any of these major bookmarking and social media sites.